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Background: Forced oscillometry is a non-invasive method to measure respiratory resistance
and reactance. In this study, we investigated the characteristics of measurements obtained
with an impulse oscillation system (IOS) for patients with interstitial lung disease (ILD).
Method: IOS and spirometry were performed in 64 ILD patients, 54 asthma patients, 49 chronic
obstructive pulmonary disease (COPD) patients, and 29 controls. Respiratory resistance and
reactance were assessed as measurements averaged over several tidal breaths (whole-breath
analysis) and as measurements separately averaged during inspiration and expiration (inspira-
toryeexpiratory analysis).
Results: Whole-breath IOS analyses for ILD patients showed increased resistance at 5 Hz and
decreased reactance at 5 Hz (X5) compared with controls, although these features were also
found in asthma and COPD patients. Inspiratoryeexpiratory analysis demonstrated that the
changes in X5 and reactance area (AX) between inspiration and expiration (DX5 and DAX,
respectively) were significantly different from those in asthma patients, COPD patients, and
controls. However, multiple linear regression analysis showed that the presence of ILD was
independently associated with DX5, but not with DAX. Furthermore, DX5 was inversely corre-
lated with vital capacity and diffusing capacity of carbon monoxide in ILD patients.
Conclusions: Our results suggest that DX5 is a characteristic feature of IOS measurements in
ILD patients, which is clearly different from those in asthma and COPD patients. This within-
breath X5 change in ILD might be associated with its severity and physiological abnormality,
although further studies are needed to investigate its cause.
ª 2013 Elsevier Ltd. All rights reserved.257 5196; fax: þ81 82 255 7360.
a-u.ac.jp (N. Hattori).
3 Elsevier Ltd. All rights reserved.
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876 A. Sugiyama et al.Introduction Materials and methodsInterstitial lung disease (ILD) is a group of lung diseases
with diverse clinical and histopathological manifestations
that share a common physiological abnormality of
restrictive ventilation.1 In patients with ILD, a static
expiratory pressureevolume curve of the lung is generally
shifted downward and rightward and spirometry results
reveal reduced vital capacity.2 However, reduced vital
capacity may occur even in patients with obstructive lung
diseases and in other situations, such as chest wall re-
striction, lung resection, inspiratory muscle weakness, or
poor cooperation with spirometry. In addition, spirometry
is sometimes difficult to perform with elderly, cognitively
impaired patients, or patients with severe respiratory
distress.3
Forced oscillometry is a non-invasive method to mea-
sure respiratory impedance and generally requires only
passive patient cooperation. Two components of respira-
tory impedance can be evaluated by forced oscillometry:
total respiratory resistance and reactance.4 Resistance at
low frequency, 5 Hz (R5), indicates total airway resistance
and resistance at high frequency, 20 Hz (R20), approxi-
mates central airway resistance. The difference between
R5 and R20 (R5  R20) is considered to be an index of the
small airways.3 Reactance at 5 Hz (X5) is thought to be
reciprocally related to compliance. The resonant fre-
quency (Fres) is the intermediate frequency at which the
total reactance is 0, and reactance area (AX) is the inte-
grated low frequency respiratory reactance magnitude
(area under the curve) between 5 Hz to Fres.5 X5, Fres, and
AX have been proposed for detecting expiratory flow
limitations.6e8
Forced oscillometry has been used primarily for pa-
tients with obstructive lung diseases because it can
sensitively detect increased airway resistance.4 Addition-
ally, Dellaca et al. reported that reactance assessed
separately during inspiration and expiration (inspirator-
yeexpiratory analysis) using forced oscillometry can
accurately detect expiratory flow limitation.6 Inspirator-
yeexpiratory analysis is useful to differentiate chronic
obstructive pulmonary disease (COPD) patients from
asthmatics who have the same degree of airflow limitation
evaluated by spirometry.7 However, characteristic findings
of forced oscillometry performed for patients with
restrictive lung diseases such as ILD have not been fully
demonstrated9e13 and, to the best of our knowledge, there
has been no published data regarding inspirator-
yeexpiratory analysis using forced oscillometry in patients
with ILD. To date, forced oscillometry has not been shown
to be able to distinguish between restrictive and
obstructive lung disease.9,10
In the present study, in order to investigate the char-
acteristics of data obtained by forced oscillometry per-
formed for patients with ILD, we measured respiratory
resistance and reactance at both inspiratory and expiratory
phases using an impulse oscillation system (IOS) in control
subjects and in patients with ILD, COPD, and asthma. We
also evaluated the relationships between the IOS mea-
surements and results from pulmonary function tests for
patients with ILD.Subjects
This was a retrospective observational study for subjects
who had spirometry tests and IOS measurements at the
Hiroshima University Hospital (Hiroshima, Japan) between
December 2007 and April 2011. We enrolled 64 patients
with ILD (36 males; mean age 65.8  0.9 years), 54 patients
with asthma (13 males; mean age 52.1  2.6 years), 49
patients with COPD (40 males; mean age 71.5  1.4 years),
and 29 control subjects (19 males; mean age 47.6  2.5
years). All ILD patients were diagnosed in accordance with
the clinical criteria established by the current ATS/ERS
guidelines.1 Patients with ILD whose forced expiratory
volume in 1 s (FEV1)/forced vital capacity (FVC) ratio was
<70% and/or who had a history of asthma were excluded
from this study. Three ILD patients whose FEV1/FVC ratios
were <70% were excluded. All 3 of these patients were
heavy smokers with rheumatoid arthritis and their CT re-
sults demonstrated the presence of apparent emphysema.
Clinical or histopathological diagnoses in the 64 enrolled
patients with ILD were: idiopathic pulmonary fibrosis (IPF)
in 26, nonspecific interstitial pneumonia (NSIP) in 17,
chronic hypersensitivity pneumonia (CHP) in 7, collagen-
vascular disease associated interstitial pneumonia (CVD-IP)
in 13, and desquamative interstitial pneumonia in one pa-
tient. Regarding CVD-IP, cases whose chest CT results
showed a usual interstitial pneumonia (UIP) or NSIP pattern
were selected. Ten patients were treated with corticoste-
roids alone, two patients were treated with corticosteroids
plus immunosuppressive agents, and one patient was
treated with an immunosuppressive agent alone. Asthma
diagnosis was made based on clinical history plus historical
evidence of reversible airway obstruction. To avoid the
possible complication of COPD, only asthmatic patients who
never smoked were enrolled. For the 54 enrolled patients,
asthma severity based on the Global Initiative for Asthma
(GINA) criteria14 was step 1 for 7 patients (13.0%), step 2 for
11 patients (20.4%), step 3 for 12 patients (22.2%), step 4
for 18 patients (33.3%), and step 5 for 6 patients (11.1%). All
enrolled asthma patients had not suffered from exacerba-
tions during the previous month. Among the 54 patients
with asthma, inhaled corticosteroids were used by 44 pa-
tients, long acting b2-agonists were used by 22 patients,
anti-leukotriene receptor antagonists were used by 14 pa-
tients, and oral theophylline was used by 11 patients. A
COPD diagnosis was based on the Global Initiative for
Obstructive Lung Disease (GOLD) criteria.15 COPD severity
according to the GOLD criteria was stage 1 (mild) for 6
patients, stage 2 (moderate) for 24, stage 3 (severe) for 18,
and stage 4 (very severe) for 1. Each enrolled COPD patient
was clinically stable. Among the 49 COPD patients, a long
acting anti-cholinergic agent was used by 20 patients, long
acting b2-agonists were used by 19 patients, and inhaled
corticosteroids were used by 13 patients. All of the control
subjects were non-current smokers who had visited the
Hiroshima University Hospital for medical health check-ups.
Spirometric results for all control subjects were FEV1/FVC
ratio >70% and vital capacity (VC) >80% of predicted.
None of the control subjects had evidence of pulmonary
Respiratory reactance in interstitial lung disease 877disease based on their histories and physical examination
results.
All subjects were informed of the possibility of being
enrolled in a retrospective observational study when they
had spirometry tests and IOS measurements, and all pro-
vided permission to use their de-identified data. The
institutional review board approved this retrospective
observational study and waived the requirement to obtain
informed consent.
Forced oscillometry
In this study, we used IOS (Eric Jaeger, Germany) to assess
respiratory impedance. IOS measurements were performed
before spirometry. Impulses were applied for 30 s during
tidal breathing in a sitting position. Subjects supported
their cheeks with both hands to reduce upper airway
shunting and wore nose clips to avoid air leaks. R5, R20,
R5  R20, X5, Fres, and AX were evaluated. We compared
the data for R5, R20, R5  R20, X5, Fres, and AX measured
at inspiratory and expiratory phases. The results for each of
these variables were determined using IOS software by
separately averaging the measurements obtained during
inspiration and expiration. Within-breath changes in X5
(DX5), defined as expiratory X5 minus inspiratory X5, and in
AX (DAX), defined as expiratory AX minus inspiratory AX,
were compared among the four groups.
Pulmonary function tests
Spirometry and diffusion capacity for carbon monoxide
(DLco) measurements were made by one specialist techni-
cian, as previously recommended.16 Predicted values for
FEV1, VC, and DLco were determined based on reference
values.17,18 DLco was determined only for the patients with
ILD using a single-breath technique. All DLco measurements
were corrected to the standard haemoglobin value ac-
cording to ERS/ATS standards.19
Statistical analysis
Results are expressed as the means  standard errors of the
means (SEMs). A value of p <0.05 was considered to indi-
cate a significant difference. The ManneWhitney test wasTable 1 Study subjects’ characteristics.
Control (n Z 29)
Male/Female 19/10
Age (years) 47.6  2.5
Body height (m) 1.65  0.02
BMI (kg/m2) 23.3  0.4
Smoking history Current/Ex/Never 0/10/19
Pack-years 3.0  1.1
VC (% predicted) 105.1  1.8
FEV1 (% predicted) 103.2  2.1
BMI Z body mass index; COPD Z chronic obstructive pulmonary
FEV1Z forced expiratory volume in 1 s. Results are means  SEMs. p
group. yp < 0.05: vs. asthma group. #p < 0.05: vs. COPD group.applied to examine differences between groups. Multiple
linear regression analysis was used to assess the relative
contributions of age, sex, height, weight, body mass index
(BMI), and smoking status (pack-years) on DX5 and DAX in
the study groups (control, asthma, COPD, and ILD). Pearson
correlation analysis was used to assess associations be-
tween DX5 and %VC or %DLco in ILD patients. A Krus-
kaleWallis test was used to compare the results for each
variable among ILD subgroups. Statistical analyses were
performed using the JMP software suite (SAS Institute).Results
The subjects enrolled in the study were classified into
control, asthma, COPD, and ILD groups. The subjects’
characteristics are summarized in Table 1. Subjects in the
COPD group were the oldest and had the highest pack-year
smoking history among the four groups. The ILD group
showed the lowest VC and the COPD group had the lowest
FEV1. The characteristics of the ILD subgroups (IPF, NSIP,
CHP, and CVD-IP) are also summarized in Supplemental
Table 1.
The whole-breath IOS results for the four groups are
shown in Table 2. The whole-breath IOS results for ILD
subgroups are also shown in Supplemental Table 2. R5
values in the control group (0.26  0.01 kPa/L/s) were
significantly lower than those in the asthma group
(0.38  0.02 kPa/L/s; p < 0.0001), the COPD group
(0.42  0.03 kPa/L/s; p < 0.0001), and the ILD group
(0.31  0.01 kPa/L/s; p < 0.05). However, R5 in the asthma
or the COPD group was shown to be significantly higher as
compared with that in the ILD group. While R20 was
significantly higher in the asthma group than in the control
group, there was no difference in R20 between the patients
with ILD and the control subjects. R5  R20 values were the
highest in the COPD group among the four groups and were
significantly higher in the asthma or the ILD group than in
the control subjects.
Regarding X5, as compared with the control subjects
(0.10  0.01 kPa/L/s), X5 values were significantly more
negative in the patients with asthma (0.16 0.01 kPa/L/s;
p< 0.01), COPD (0.20 0.02 kPa/L/s; p< 0.0001), and ILD
(0.16 0.01 kPa/L/s; p< 0.0001). Fres and AX values in the
asthma, COPD, and ILD groups were significantly higher thanAsthma (n Z 54) COPD (n Z 49) ILD (n Z 64)
13/41* 40/9y 36/28y#
52.1  2.6 71.5  1.4*y 65.8  0.9*y#
1.55  0.01* 1.61  0.01*y 1.58  0.01*y
23.0  0.6 21.8  0.4* 23.1  0.5
0/0/54 9/38/2 6/35/23
0* 53.9  3.8*y 27.5  3.5*y#
95.1  2.6* 87.6  2.9*y 76.1  2.6*y#
86.1  2.8* 58.5  2.6*y 79.6  2.4*#
disease; ILD Z interstitial lung disease; VC Z vital capacity;
-Values are not significant unless indicated. *p < 0.05: vs. control
Table 2 Whole-breath IOS results.
Control (n Z 29) Asthma (n Z 54) COPD (n Z 49) ILD (n Z 64)
R5 (kPa/l/s) 0.26  0.01 0.38  0.02* 0.42  0.03* 0.31  0.01*y#
R20 (kPa/l/s) 0.24  0.01 0.32  0.01* 0.28  0.01y 0.24  0.01y
R5  R20 (kPa/l/s) 0.02  0.01 0.07  0.01* 0.13  0.02*y 0.07  0.01*#
X5 (Pa/l/s) 0.10  0.01 0.16  0.01* 0.20  0.02* 0.16  0.01*
Fres (Hz) 10.57  0.57 14.82  0.71* 20.76  0.98*y 15.74  0.51*#
AX (kPa/l/s Hz) 0.28  0.02 0.79  0.13* 1.56  0.22*y 0.77  0.01*#
COPD Z chronic obstructive pulmonary disease; ILD Z interstitial lung disease; R5 Z resistance at 5 Hz; R20 Z resistance at 20 Hz;
X5Z reactance at 5 Hz; FresZ resonant frequency; AXZ reactance area. Results are means  SEMs. p-values are not significant unless
indicated. *p < 0.05: vs. control group. yp < 0.05: vs. asthma group. #p < 0.05: vs. COPD group.
878 A. Sugiyama et al.those for the control subjects. Next, we separately calcu-
lated the average values for R5, R20, R5 R20, X5, Fres, and
AX during expiration and inspiration; thesewithin-breath IOS
measurements are shown in Table 3. The within-breath IOS
results for subgroups of ILD (IPF, NSIP, CHP, and CVD-IP) are
also shown in Supplemental Table 3. As shown in Fig. 1A,
expiratory R5 was significantly higher than inspiratory R5 in
all groups. Similarly, expiratory R20 was higher than inspi-
ratory R20 in all groups but a statistically significant differ-
ence was not observed in the patients with COPD (Fig. 1B).
Interestingly, expiratory R5  R20 was significantly
higher than inspiratory R5  R20 in the COPD group,
whereas there were no significant differences in R5  R20
between expiration and inspiration in the asthma group,
the ILD group, and the control subjects. In contrast to the
changes in R5 and R20 between expiration and inspiration,
the changes in X5 between inspiration and expiration were
found to vary among the four groups (Fig. 1C). In theTable 3 Inspiratoryeexpiratory IOS results.
Control (n Z 29) Asthma (n Z
R5 (kPa/l/s)
Expiratory 0.28  0.02x 0.41  0.0
Inspiratory 0.23  0.01 0.34  0.0
R20 (kPa/l/s)
Expiratory 0.26  0.02x 0.33  0.0
Inspiratory 0.22  0.01 0.29  0.0
R5  R20 (kPa/l/s)
Expiratory 0.02  0.01 0.08  0.0
Inspiratory 0.01  0.01 0.05  0.0
X5 (kPa/l/s)
Expiratory 0.10  0.01 0.16  0.0
Inspiratory 0.11  0.01 0.16  0.0
DX5 0.02  0.01 0.00  0.0
Fres (Hz)
Expiratory 10.70  0.67 15.30  0.8
Inspiratory 10.46  0.49 13.80  0.6
AX (kPa/l/s Hz)
Expiratory 0.26  0.05 0.88  0.1
Inspiratory 0.28  0.05 0.67  0.1
DAX 0.02  0.03 0.22  0.0
COPD Z chronic obstructive pulmonary disease; ILD Z interstitial lu
X5Z reactance at 5 Hz; FresZ resonant frequency; AXZ reactance a
indicated. *p < 0.05: vs. control group. yp < 0.05: vs. asthma group.control subjects and the patients with asthma, there was
no significant difference between expiratory X5 and inspi-
ratory X5. In the patients with COPD, expiratory X5
(0.23  0.03 kPa/L/s) was more negative than inspiratory
X5 (0.16  0.01 kPa/L/s) (p < 0.05). In the patients with
ILD, however, expiratory X5 (0.14  0.013 kPa/L/s) was
found to be significantly less negative than inspiratory X5
(0.19  0.01 kPa/L/s) (p < 0.0001).
In the ILD group, there was a trend for increased inspi-
ratory AX (0.86  0.08 kPa/L/s) compared to expiratory AX
(0.74  0.07 kPa/L/s), whereas Fres did not differ between
inspiration (15.54  0.47 kPa/L/s) and expiration
(15.89  0.57 kPa/L/s) (Table 3). Supporting the changes
seen in X5 between expiration and inspiration among the
four groups, DX5 in the ILD group (0.04  0.01 kPa/L/s) was
significantly higher than those in the other three groups,
and DX5 in the COPD group (0.08  0.02 kPa/L/s) was
significantly lower than those in the other three groups54) COPD (n Z 49) ILD (n Z 64)
2*x 0.45  0.03*x 0.32  0.01y#x
2* 0.37  0.02* 0.29  0.01*y#
1*x 0.30  0.01y 0.25  0.01y#x
1* 0.26  0.01*y 0.22  0.01y#
1* 0.16  0.02*yx 0.07  0.01*#
1* 0.10  0.01*y 0.07  0.01*#
2* 0.23  0.03*yx 0.14  0.01*#x
1* 0.16  0.01* 0.19  0.01*y#
1 0.08  0.02*y 0.04  0.01*y#
2* 21.75  1.02*yx 15.89  0.57*#
2* 19.04  0.96*y 15.54  0.47*y#
5* 1.87  0.24*yx 0.74  0.07*#
0* 1.04  0.12*y 0.86  0.08*y
8* 0.82  0.18*y 0.12  0.06*y#
ng disease; R5 Z resistance at 5 Hz; R20 Z resistance at 20 Hz;
rea. Results are means  SEMs. p-values are not significant unless
#p < 0.05: vs. COPD group. xp < 0.05: vs. inspiratory phase.
Figure 1 Comparisons of the mean values for resistance at 5 Hz (R5) (A), resistance at 20 Hz (R20) (B) and reactance at 5 Hz (X5)
(C) during expiration and inspiration in the control (n Z 29), asthma (n Z 54), chronic obstructive pulmonary disease (COPD)
(n Z 49), and interstitial lung disease (ILD) (n Z 64) groups. Error bars indicate standard errors of the mean. *: p < 0.05; **:
p < 0.01; ***: p < 0.0001.
Respiratory reactance in interstitial lung disease 879(Fig. 2A). In addition, DAX values in the ILD group were
significantly different from those in the other three groups
(Fig. 2B). Among the asthma, COPD, ILD, and control
groups, the variables of age, sex, height, weight, BMI, and
smoking status (pack-years) were not completely matched;
these differences might have affected the DX5 and DAX
values. Therefore, we used multiple linear regression
analysis to determine what variables were significantly
associated with DX5 or DAX levels.
This analysis showed that DX5 was independently asso-
ciated with the presence of COPD (bZ 0.428; p < 0.0001)
or ILD (bZ 0.192; pZ 0.037), but was not associated with
age, sex, height, weight, BMI, or smoking status (pack-year)
(Table 4). The only significant variable associated with DAX
was the presence of COPD. An independent association
between the presence of ILD and DAX was not found. This
result implied that DX5 was a more characteristic feature
of IOS measurements in ILD patients than was DAX (Table
4). Based on these results, relationships between DX5 and
measurements of pulmonary function tests (%VC and %
DLco) were analysed for ILD patients (Fig. 3). DX5 was
inversely correlated with %VC (rZ 0.43; p < 0.001) and %
DLco (r Z 0.57; p < 0.0001).Figure 2 Comparison of the mean values for DX5 (expiratoryein
atoryeinspiratory values of the reactance area) (B) in the control
chronic obstructive pulmonary disease (COPD) (n Z 49), and pat
indicate standard errors of the mean. *: p < 0.05; **: p < 0.01; ***Discussion
In the present study, the characteristics of IOS measure-
ments made for patients with ILD were described in detail.
To the best of our knowledge, this is the first report to
compare IOS data between patients with restrictive and
obstructive lung diseases. Whole-breath IOS analyses for
ILD patients showed increased R5 and decreased X5
compared with controls, although these features were also
found in the asthma and COPD groups. However, changes in
IOS measurement results, particularly X5 and AX, between
inspiration and expiration were characteristic features in
asthma, COPD, and ILD. Inspiratory and expiratory X5 did
not differ in the control subjects and the patients with
asthma. The magnitudes of expiratory X5 were greater than
those of inspiratory X5 in the patients with COPD, while this
situation was found to be reversed in the patients with ILD.
Similarly, the within-breath changes in AX were signifi-
cantly lower in ILD patients than those in asthma or COPD
patients; however, multiple linear regression analysis
showed that the presence of ILD was not independently
associated with DAX. These results indicate that patients
with ILD show completely different characteristics ofspiratory values of the reactance at 5 Hz) (A) and DAX (expir-
group (n Z 29), patients with asthma (n Z 54), patients with
ients with interstitial lung disease (ILD) (n Z 64). Error bars
: p < 0.0001.
Table 4 Multiple linear regression analysis for DX5 and DAX.
Variables DX5 DAX
Standardized coefficient (b) p-Value Standardized coefficient (b) p-Value
Age 0.006 0.946 0.046 0.601
Sex 0.055 0.548 0.045 0.634
Height 0.186 0.656 0.247 0.565
Weight 0.267 0.687 0.456 0.503
BMI 0.027 0.958 0.607 0.244
Smoking (pack-years) 0.074 0.417 0.082 0.382
Control 0.072 0.350 0.119 0.131
COPD 0.428 <0.0001 0.449 <0.0001
ILD 0.192 0.037 0.047 0.616
BMI Z body mass index; COPD Z chronic obstructive pulmonary disease; ILD Z interstitial lung disease. Sex: female Z 0, male Z 1;
Control: noZ 0, yesZ 1; COPD: noZ 0, yesZ 1; ILD: noZ 0, yesZ 1. The presence of asthma was excluded from this multiple linear
regression model.
880 A. Sugiyama et al.within-breath changes in X5 as compared with asthma and
COPD patients. In addition, a significant correlation be-
tween DX5 and %VC or %DLco suggests that the within-
breath change in X5 may be associated with a physiological
abnormality in ILD.
The most interesting finding of this study was that the
within-breath change in X5 was a distinguishable charac-
teristic of ILD as compared with the change in asthma or
COPD. As previously reported, there was no difference in X5
by whole-breath oscillometry between ILD and asthma or
COPD.9,10 The magnitude of inspiratory X5 was shown to be
greater than that of expiratory X5 in the patients with ILD.
Consistent with the results of previous studies,3,6e8 the
inspiratory and expiratory X5 did not differ in the asthma
patients and the magnitude of inspiratory X5 was smaller
than that of expiratory X5 in the patients with COPD. X5 is a
numerically negative value thought to be related to the
reciprocal of lung compliance.5,20 Therefore, its value be-
comes more negative when the peripheral lung tissue has
reduced compliance or is compressed.20,21 Because the
distensibility of peripheral lung tissue is decreased in pa-
tients with ILD,2 compliance during inspiration is likely to
be more reduced compared with that during expiration.
This might be a reason why the magnitude of inspiratory X5Figure 3 Relationship between DX5 and VC% predicted (A) or DL
(n Z 64). DX5: within-breath change in reactance at 5 Hz (expirato
capacity of carbon monoxide.was greater than that of expiratory X5 in patients with ILD.
Furthermore, the different patterns of within-breath
changes in X5 among the patients with asthma, COPD,
and ILD suggest that inspiratoryeexpiratory analysis using
IOS might be useful not only for obstructive lung disease but
also for ILD. Further investigations will be needed to
identify the cause(s) of these differences of within-breath
changes in X5.
Another interesting finding of this study was that DX5
showed significant inverse correlations with VC and DLco in
patients with ILD. Because reduced lung volume and diffu-
sion capacity are associated with ILD disease severity and
prognosis,22,23 our results may support the association be-
tween DX5 and disease severity or physiological abnormality
in ILD. The inverse correlation between DX5 and VCmay also
suggest an association between increased DX5 and reduced
lung distensibility in ILD. In addition, the greater magnitude
ofDX5 resulting fromexaggerated inspiratory reactancemay
reflect an increased elastic recoil during inspiration in ILD.
For patients with ILD, whole-breath analyses of IOS
demonstrated that R5 and R5  R20 were increased, but
that R20 was similar compared with those of the control
subjects. Resistance represents the frictional components
of the respiratory tract and is predominantly influenced byco% predicted (B) in the patients with interstitial lung disease
ry X5 minus inspiratory X5). VC: vital capacity. DLco: diffusing
Respiratory reactance in interstitial lung disease 881the calibre of the central airways. Pressure oscillation at
high frequency is severely dampened before reaching the
peripheral airways, but it penetrates much further into the
lung periphery at low frequency. Thus, R5 reflects total
respiratory resistance, whereas R20 reflects central airway
resistance. The difference between R5 and R20 (R5  R20)
is thought to be an index of the small airways.3 Based on
these observations, R5, R20, and R5  R20 results from ILD
patients may suggest the presence of small airway dis-
ease24; however, these results were not distinguishable
from those for obstructive lung diseases.10 In addition,
inspiratoryeexpiratory analyses of R5, R20, and R5  R20
failed to discriminate ILD from obstructive lung diseases
(Fig. 1A and B, Table 3). These results suggest that resis-
tance measured using IOS cannot reveal the characteristics
of ILD; however, inspiratoryeexpiratory analysis of reac-
tance might show a distinctive pattern for ILD.
Although promising results were obtained, we are aware
that this study has limitations. First, the number of the
patients included in the study was relatively small. To
verify the results, a larger sample size study is necessary.
Secondly, for the data analysis, we used the raw values
measured by IOS for various ages of subjects, since defini-
tive predictive equations have not yet been established.
Again, a large-scale study across a wider age range is
needed to validate existing reference values.9
Conclusion
We have demonstrated that an increased magnitude of X5
during inspiration compared to X5 during expiration was a
characteristic finding in inspiratoryeexpiratory analysis of
IOS performed for patients with ILD. Significant inverse
correlations between the magnitude of inspirator-
yeexpiratory difference in X5 (DX5) and VC or DLco were
observed, and these data may suggest an association be-
tween DX5 and severity and physiological abnormality in
patients with ILD. DX5 results showed clearly different
patterns among patients with asthma, COPD, and ILD.
Exaggerated inspiratory reactance in ILD may reflect
reduced distensibility and increased elastic recoil of the
lung during inspiration, although further studies are needed
to investigate its cause.
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